---
pmid: '26395742'
title: Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy
  in Type 1 Diabetes.
authors:
- Zampetaki A
- Willeit P
- Burr S
- Yin X
- Langley SR
- Kiechl S
- Klein R
- Rossing P
- Chaturvedi N
- Mayr M
journal: Diabetes
year: '2016'
full_text_available: false
doi: 10.2337/db15-0389
---

# Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes.
**Authors:** Zampetaki A, Willeit P, Burr S, Yin X, Langley SR, Kiechl S, Klein R, Rossing P, Chaturvedi N, Mayr M
**Journal:** Diabetes (2016)
**DOI:** [10.2337/db15-0389](https://doi.org/10.2337/db15-0389)

## Abstract

1. Diabetes. 2016 Jan;65(1):216-27. doi: 10.2337/db15-0389. Epub 2015 Sep 22.

Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy 
in Type 1 Diabetes.

Zampetaki A(1), Willeit P(2), Burr S(1), Yin X(1), Langley SR(1), Kiechl S(3), 
Klein R(4), Rossing P(5), Chaturvedi N(6), Mayr M(7).

Author information:
(1)King's British Heart Foundation Centre of Research Excellence, King's College 
London, London, U.K.
(2)King's British Heart Foundation Centre of Research Excellence, King's College 
London, London, U.K. Department of Public Health and Primary Care, University of 
Cambridge, Cambridge, U.K. Department of Neurology, Medical University of 
Innsbruck, Innsbruck, Austria.
(3)Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
(4)Department of Ophthalmology and Visual Sciences, University of 
Wisconsin-Madison, Madison, WI.
(5)Steno Diabetes Centre, University of Copenhagen, Copenhagen, Denmark.
(6)Institute of Cardiovascular Science, University College London, London, U.K. 
n.chaturvedi@ucl.ac.uk manuel.mayr@kcl.ac.uk.
(7)King's British Heart Foundation Centre of Research Excellence, King's College 
London, London, U.K. n.chaturvedi@ucl.ac.uk manuel.mayr@kcl.ac.uk.

Comment in
    Diabetes. 2016 Jan;65(1):22-4. doi: 10.2337/dbi15-0028.

Circulating microRNAs (miRNAs) have emerged as novel biomarkers of diabetes. The 
current study focuses on the role of circulating miRNAs in patients with type 1 
diabetes and their association with diabetic retinopathy. A total of 29 miRNAs 
were quantified in serum samples (n = 300) using a nested case-control study 
design in two prospective cohorts of the DIabetic REtinopathy Candesartan Trial 
(DIRECT): PROTECT-1 and PREVENT-1. The PREVENT-1 trial included patients without 
retinopathy at baseline; the PROTECT-1 trial included patients with 
nonproliferative retinopathy at baseline. Two miRNAs previously implicated in 
angiogenesis, miR-27b and miR-320a, were associated with incidence and with 
progression of retinopathy: the odds ratio per SD higher miR-27b was 0.57 (95% 
CI 0.40, 0.82; P = 0.002) in PREVENT-1, 0.78 (0.57, 1.07; P = 0.124) in 
PROTECT-1, and 0.67 (0.50, 0.92; P = 0.012) combined. The respective odds ratios 
for higher miR-320a were 1.57 (1.07, 2.31; P = 0.020), 1.43 (1.05, 1.94; P = 
0.021), and 1.48 (1.17, 1.88; P = 0.001). Proteomics analyses in endothelial 
cells returned the antiangiogenic protein thrombospondin-1 as a common target of 
both miRNAs. Our study identifies two angiogenic miRNAs, miR-320a and miR-27b, 
as potential biomarkers for diabetic retinopathy.

Â© 2016 by the American Diabetes Association. Readers may use this article as 
long as the work is properly cited, the use is educational and not for profit, 
and the work is not altered.

DOI: 10.2337/db15-0389
PMID: 26395742 [Indexed for MEDLINE]
